Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib

Annals of Oncology

Volumn 22, Issue 4, 2011, Pages 794-800

  Beuselinck, B ^a,b   Oudard, S ^a,b   Rixe, O ^c   Wolter, P ^d   Blesius, A ^e   Ayllon, J ^a   Elaidi, R ^a   Schoffski P ^d   Barrascout, E ^a   Morel, A ^a   Escudier, B ^e   Lang, H ^f   Zucman Rossi, J ^a,b   Medioni, J ^a,g  

^a ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^b Université Paris 13   (France)

^c UNIVERSITY OF CINCINNATI   (United States)

^d UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^e INSTITUT GUSTAVE ROUSSY   (France)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Bone metastases; Outcome; Renal cell carcinoma; Sunitinib

Indexed keywords

ALPHA INTERFERON; CALCIUM; INTERLEUKIN 2; SUNITINIB;

ADULT; ARTICLE; BONE METASTASIS; BRAIN METASTASIS; CALCIUM BLOOD LEVEL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HUMAN; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEPHRECTOMY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; THROMBOCYTE COUNT;

EID: 79953307244     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdq554     Document Type: Article

References (17)

1. Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics. 2006. CA Cancer J Clin 2006; 56: 106-130.
3. Lam JS, Leppert JT, Belldegrun AS, Figlin R. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005; 23: 202-212.
4. US National Institutes of Health. Surveillance, epidemiology and end results (SEER) cancer statistics review: kidney and renal pelvis cancer. 5-year relative survival rates, 1996-2002. http://seer.cancer.gov/cgi-bin/csr/1975_2007/search.pl#results (August 2010, date last accessed).
5. Oudard S, George D, Medioni J, Motzer R. Treatment options in renal cell carcinoma: past, present and future. Ann Oncol 2007; 18 (suppl 10): x25-x31.
6. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124.
7. Motzer R, Mazumdar M, Bacik J et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17: 2530-2540.
8. Motzer R, Bacik J, Mazumbar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan Kettering Cancer Center experience. Clin Cancer Res 2004; 10: 6202S-6203S.
9. Mekhail T, Abou-Jawde R, Boumerhi G et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 832-841.
10. Motzer R, Bukowski R, Figlin R et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113: 1552-1558.
11. Choueiri T, Garcia J, Elson P et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110: 543-550.
12. Heng D, Wanling X, Meredith M et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27: 5794-5799.
13. Sahi C, Knox J, Clemons M et al. Renal cell carcinoma bone metastases: clinical advances. Ther Adv Med Oncol 2010; 2: 75-83.
14. Patil S, Figlin R, Hutson T et al. Prognostic factors for overall survival with sunitinib as first-line therapy in patients with metastatic renal cell carcinoma. In ASCO Annual Meeting (Abstr 5042). 2009.
15. Riechelmann R, Chin S, Wang L et al. Sorafenib for metastatic renal cancer: the Princess Margaret experience. Am J Clin Oncol 2008; 31: 182-187.
16. Badalian G, Derecskei K, Szendroi A et al. EGFR and VEGFR2 protein expressions in bone metastases of clear cell renal cancer. Anticancer Res 2007; 27: 889-894.
17. Zolnierek J, Nurzynski P, Langiewicz P et al. Efficacy of targeted therapy in patients with renal cell carcinoma with pre-existing or new bone metastases. J Cancer Res Clin Oncol 2010; 136: 371-378.